Kyverna Total Operating Expenses from 2010 to 2026
| KYTX Stock | 7.93 0.66 9.08% |
Total Operating Expenses | First Reported 2010-12-31 | Previous Quarter 161.5 M | Current Value 169.6 M | Quarterly Volatility 49.1 M |
Check Kyverna Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kyverna Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 18.4 M, Interest Income of 18.5 M or Depreciation And Amortization of 1.5 M, as well as many indicators such as Price To Sales Ratio of 136, Dividend Yield of 0.0 or PTB Ratio of 0.46. Kyverna financial statements analysis is a perfect complement when working with Kyverna Therapeutics Valuation or Volatility modules.
Kyverna | Total Operating Expenses | Build AI portfolio with Kyverna Stock |
The evolution of Total Operating Expenses for Kyverna Therapeutics Common provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Kyverna Therapeutics compares to historical norms and industry peers.
Latest Kyverna Therapeutics' Total Operating Expenses Growth Pattern
Below is the plot of the Total Operating Expenses of Kyverna Therapeutics Common over the last few years. It is the total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses. Kyverna Therapeutics' Total Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kyverna Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Operating Expenses | 10 Years Trend |
|
Total Operating Expenses |
| Timeline |
Kyverna Total Operating Expenses Regression Statistics
| Arithmetic Mean | 56,044,905 | |
| Geometric Mean | 44,317,989 | |
| Coefficient Of Variation | 87.53 | |
| Mean Deviation | 36,253,031 | |
| Median | 32,002,000 | |
| Standard Deviation | 49,053,738 | |
| Sample Variance | 2406.3T | |
| Range | 137.6M | |
| R-Value | 0.71 | |
| Mean Square Error | 1267.6T | |
| R-Squared | 0.51 | |
| Significance | 0 | |
| Slope | 6,910,878 | |
| Total Sum of Squares | 38500.3T |
Kyverna Total Operating Expenses History
About Kyverna Therapeutics Financial Statements
Kyverna Therapeutics investors use historical fundamental indicators, such as Kyverna Therapeutics' Total Operating Expenses, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Kyverna Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Operating Expenses | 161.5 M | 169.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Kyverna Stock Analysis
When running Kyverna Therapeutics' price analysis, check to measure Kyverna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kyverna Therapeutics is operating at the current time. Most of Kyverna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kyverna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kyverna Therapeutics' price. Additionally, you may evaluate how the addition of Kyverna Therapeutics to your portfolios can decrease your overall portfolio volatility.